PRIMARY STUDY
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
Key Findings: THCV is a new potential treatment against obesity-associated glucose intolerance with pharmacology different from that of CB1 inverse agonists/antagonists.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Italy, United Kingdom
Year of Pub: 2013
Cannabinoids Studied: AM-x Synthetic Cannabinoids, Cannabinoid (unspecified), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1
Dosage: Study 1: THCV 0.3, 1, 2.5, 5 and 12.5 mg kg−1, oral twice daily for 30 days. Study 2: THCV 0.1, 0.5, 2.5 and 12.5 mg kg−1, oral, once daily for 45 days.
Route of Administration: Oral (Ingestion)
Link to study
